CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Secukinumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03623867
NCT03623867Phase 4Completed
CompareCT.gov

Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab

Chinese University of Hong Kong·interventional·Posted Aug 9, 2018·Updated Sep 6, 2023

In Brief

A Phase 4 clinical trial evaluating Secukinumab and Placebo for Psoriatic Arthritis. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment pathway through anti IL-17 gives promising clinical improvement. Yet, its effect on radiographic progression remains uncertain. This study aimed to ascertain the effect of secukinumab on structural progression in PsA by evaluation through high resolution peripheral quantative computed tomography (HRpqCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesHong Kong
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedAug 9, 2018
Enrollment StartMay 18, 2020
Primary CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.9 years ago

Interventions

Secukinumabdrug

Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48

Placebodrug

Subject will take placebo once weekly in week 0-4, and once monthly till week 48